65,437 trials
Advanced Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) as Assessed by the Investigator — 37.1; 40.6 percentage of participants
Tobacco Use Disorder/Cigarette Smoking
Primary: Delay Discounting — -5.21; -6.57; -7.13 k-value — p=.29
Cerebral Stroke · Hemiplegia, Spastic
Primary: Differences in Spatial Measurements of Trunk Dislocation Components During 3-directional Bell-reaching Task Between Healthy Subjects and Stroke Patients — 272.44…
Pediculosis Capitis · Lice Infestations · Head Lice
Primary: Proportion of Participants Who Are Completely Free of Live Lice — 0.00; 0.00; .535; .200 proportion of subjects free of live lice — p=.025
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
Septic Shock
Primary: 90-day Mortality — 323; 329 Participants
Muscular Dystrophies · Muscular Dystrophy, Duchenne · Muscular Disorders, Atrophic
Primary: Change From Baseline in Functional Capacity as Assessed by the Mid-level (Elbow) Dimension Score of the Performance of Upper Limb (PUL) Version 1.2 at Month 12 — 65.5…
Cardiovascular Diseases
Primary: Change in Hippocampal Volume — -15.4; -49.9 mm^3
Dermatitis, Seborrheic · Dry Skin; Eczema
Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001
Healthy
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) — 0.73 milliseconds (msec)
COVID-19 Disease
Primary: Neutralizing Antibody Titers Against the SARS-CoV-2 Index Virus (Wuhan Wild Type Isolate) at 2 Weeks After Trial Vaccination — 1018.1; 1060.6; 1259.0; 1619.6 titer…
Congenital Adrenal Hyperplasia
Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003
Genetic Predisposition · Genetic Hypertension
Primary: Left Ventricular Mass — 155.1680523; 129.5013331 gram
Pulmonary Fibrosis
Primary: Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants — -2.807; -3.068; -1.120 Percent change from baseline in ppFVC
Childhood Mortality
Primary: All-cause Mortality Rate in Children Aged 1-59 Months — 8.2; 10.0 deaths per 1000 person years